Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 3010-3014

  Loureiro, Silvia ^a   Ren, Junyuan ^a   Phapugrangkul, Pongsathon ^a   Colaco, Camilo A ^b   Bailey, Christopher R ^b   Shelton, Holly ^c   Molesti, Eleonora ^d   Temperton, Nigel J ^d   Barclay, Wendy S ^c   Jones, Ian M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b ImmunoBiology Limited   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEMAGGLUTIN FC RECEPTOR FUSION PROTEIN; HYBRID PROTEIN; INFLUENZA VACCINE; PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; CROSS REACTION; DRUG SYNTHESIS; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEROCONVERSION; VIRUS HEMAGGLUTINATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELL LINE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INSECTS; MICE; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

AVES; HEXAPODA; MUS; ORTHOMYXOVIRIDAE;

EID: 79952418476     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01241-10     Document Type: Article

References (40)

1. Auewarakul, P., et al. 2007. An avian influenza H5N1 virus that binds to a human-type receptor. J. Virol. 81:9950-9955. (Pubitemid 350067698)
2. Ayora-Talavera, G., et al. 2009. Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium. PLoS One 4:e7836.
3. Barclay, W. S., et al. 2007. Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. Bioorg. Med. Chem. 15:4038-4047.
4. Bright, R. A., et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878. (Pubitemid 46589748)
5. Chen, H., X. Xu, and I. M. Jones. 2007. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 4:33.
6. Cox, M. M. 2008. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 10:56-61.
7. Cox, M. M., and D. Karl Anderson. 2007. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respi. Viruses 1:35-40.
8. Cox, M. M., P. A. Patriarca, and J. Treanor. 2008. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi. Viruses 2:211-219.
9. Fichera, E., D. Felnerova, R. Mischler, J. F. Viret, and R. Glueck. 2009. New strategies to overcome the drawbacks of currently available flu vaccines. Adv. Exp. Med. Biol. 655:243-252.
10. Hensley, S. E., et al. 2009. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736.
11. Kang, S. M., P. Pushko, R. A. Bright, G. Smith, and R. W. Compans. 2009. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 333:269-289.
12. Kashyap, A. K., et al. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U. S. A. 105:5986-5991.
13. Kaverin, N. V., et al. 2007. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J. Virol. 81:12911-12917. (Pubitemid 350156928)
14. Kopecky-Bromberg, S. A., and P. Palese. 2009. Recombinant vectors as influenza vaccines. Curr. Top. Microbiol. Immunol. 333:243-267.
15. Lakey, D. L., et al. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:838-841.
16. Lambkin, R., L. McLain, S. E. Jones, S. L. Aldridge, and N. J. Dimmock. 1994. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J. Gen. Virol. 75(Pt. 12):3493-3502.
17. Leroux-Roels, I., et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
18. Li, J., et al. 2009. Fine antigenic variation within H5N1 influenza virus hemagglutinin's antigenic sites defined by yeast cell surface display. Eur. J. Immunol. 39:3498-3510.
19. Licastro, F., M. Chiappelli, M. Ianni, and E. Porcellini. 2009. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. Int. J. Immunopathol. Pharmacol. 22:567-572.
20. Mathewson, A. C., et al. 2008. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J. Gen. Virol. 89:2741-2745.
21. Metheringham, R. L., et al. 2009. Antibodies designed as effective cancer vaccines. MAbs 1:71-85.
22. Pengelley, S. C., et al. 2006. A suite of parallel vectors for baculovirus expression. Protein Expr. Purif. 48:173-181.
23. Pleass, R. J. 2009. Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol. 31:529-538.
24. Reagan-Shaw, S., M. Nihal, and N. Ahmad. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661. (Pubitemid 351348146)
25. Reichert, J. M. 2011. Antibody-based therapeutics to watch in 2011. MAbs 3:76-99.
26. Schmidt, S. R. 2009. Fusion-proteins as biopharmaceuticals - applications and challenges. Curr. Opin. Drug Discov. Devel. 12:284-295.
27. Stevens, J., et al. 2006. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-410.
28. Temperton, N. J., et al. 2007. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses 1:105-112.
29. Tosh, P. K., R. M. Jacobson, and G. A. Poland. 2010. Influenza vaccines: from surveillance through production to protection. Mayo Clin. Proc. 85:257-273.
30. Treanor, J. J., et al. 2006. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 193:1223-1228.
31. Tripp, R. A., and S. M. Tompkins. 2008. Recombinant vaccines for influenza virus. Curr. Opin. Invest. Drugs 9:836-845.
32. Wang, T. T., et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 107:18979-18984.
33. Wang, T. T., et al. 26 February 2010, posting date. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796.
34. Wang, W., et al. 2010. The hemagglutin protein 158N glycosylation and receptor binding specificity synergistically affect antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J. Virol. 84:6570-6577.
35. Weldon, W. C., et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466.
36. Yamada, S., et al. 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382. (Pubitemid 44764114)
37. Yang, Z. Y., et al. 2007. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317:825-828.
38. Zelenetz, A. D., and R. Levy. 1990. Directional cloning of cDNA using a selectable SfiI cassette. Gene 89:123-127. (Pubitemid 20209024)
39. Zhang, M. Y., Y. Wang, M. K. Mankowski, R. G. Ptak, and D. S. Dimitrov. 2009. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 27:857-863.
40. Zhao, Y., D. A. Chapman, and I. M. Jones. 2003. Improving baculovirus recombination. Nucleic Acids Res. 31:E6. doi:10.1093/nar/gng006.